Otsuka Pharmaceutical Co., Ltd.

[Contact Information]
Otsuka Pharmaceutical Co., Ltd.
Shinagawa Grand Central Tower
2-16-4 Konan, Minato-ku, Tokyo 108-8242, Japan
Attn: Global Business Development
Phone: +81-3-6717-1400
Fax: +81-3-6717-1408
E-mail: Business_Development@otsuka.jp
Partnering and Open Innovation
Otsuka Pharmaceutical Co., Ltd.
Partnering Focus

Leverage strategic partnerships to address areas of high unmet medical need in CNS, oncology, and cardio-renal diseases.

**Asset Strategy**
- Unique and novel mechanism of action
- Significant differentiation with competitors
- Synergies with our current portfolio

**Therapeutic Area**
- **Global**
  - CNS
  - Cancer
  - Renal
- **Japan only**
  - GI and CV
  - Ophthalmology
  - Dermatology

**Development Stage**
- From early phase to Launched

**Target / Technology Type**
- Small molecules
- Biologics
- Allogeneic cell therapy
- Gene therapy
- Any other innovative technologies
## Therapeutic Areas of Interest for Details

### Psychiatry
- Schizophrenia
- Bipolar Disorder
- Major Depressive Disorder (MDD)
- Post Traumatic Stress Disorder (PTSD)
- Attention Deficit and Hyperactivity Disorder (ADHD)
- Intermittent Explosive Disorder (IED)
- Traumatic Brain Injury (behavior)
- Neuropathy (e.g., Spinal Muscular Atrophy)

### Neurology
- Cluster Headaches
- Epilepsy
- Neuropathic Pain
- Parkinson’s Disease (disease modifier)
- Alzheimer’s Disease (behavior, cognition)
- Migraine (acute and prevention)
- Degenerative Disorders (ALS, DMD, Huntington’s Disease)

### Oncology
- Hematology
- Novel MoA in Solid Tumors

### Renal
- Polycystic Kidney Disease (PKD)
- Chronic Kidney Disease (CKD)
- Acute Kidney Injury (AKI)
- Immune-mediated renal disease
- Management in patients with CKD